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Abstract
Development of iniparib as an anti-cancer agent was hindered in part by lingering questions
regarding its mechanism of action, the activity of its metabolites, and their potential accumu-
lation in tumors. Due to strong similarities in metabolism of iniparib between humans and
dogs, a veterinary clinical trial in pet dogs with spontaneous cancers was designed to
answer specific questions pertaining to pharmacokinetic exposures and tolerability of ini-
parib. Dogs were treated with iniparib alone and in combination with carboplatin chemother-
apy. Iniparib doses ranged between 10–70 mg/kg intravenously (IV). Plasma, tumor and
normal tissue samples were collected before and at various time points scheduled after
exposure for pharmacokinetic and biologic analysis. The primary endpoints included char-
acterization of dose-limiting toxicities (DLT) and determination of the drug exposures that
could be achieved in both normal and tumor tissues. Nineteen dogs were treated. DLT
included fever, anorexia, diarrhea, neutropenia, and thrombocytopenia; most effects were
attributable to carboplatin based on the timing of adverse event onset. The maximum toler-
ated dose (MTD) of iniparib was not identified. Moderate to high variability in plasma expo-
sure was noted for iniparib and all metabolites between animals. When quantifiable, iniparib
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and metabolite plasma:tumor ratios were < 0.088 and <1.7, respectively. In this study, ini-
parib was well tolerated as a single agent and in combination with carboplatin over a range
of doses. However, clinically relevant concentrations of the parent drug and selected
metabolites were not detectable in canine tumor tissues at any studied dose, thus eliminat-
ing expectations for clinical responses in dogs or humans. Negative clinical trials in humans,
and the uncertainties of its mechanism of action, ultimately led to the decision to stop clinical
development of the drug. Nevertheless, the questions that can be asked and answered
within the comparative oncology approach are evident from this successfully executed com-
parative clinical trial and exemplify the value of such studies in drug development.
Introduction
Iniparib (4-iodo-3-nitrobenzamide; BSI-201) is a highly lipophilic small-molecule prodrug
that is metabolized to an active C-nitroso intermediate. Known downstream metabolites from
this active intermediate include INBA (4-iodo-3-nitrosobenzamide), and IABM (4-iodo-
3-amino-benzamide), but their distinct anti-cancer potencies are unknown. The proposed
detoxification pathway of iniparib metabolism results in the production of several distinct con-
jugates and IABA (4-iodo-3-amino-benzoic acid). Iniparib was initially developed as a poly
adenosine diphosphate ribose polymerase 1 (PARP1) inhibitor; however, current knowledge
indicates that its activity is not linked to PARP inhibition as originally thought.[1,2] The inte-
gration of iniparib into cancer treatment protocols was originally supported by encouraging
results from initial human clinical trials, specifically in the treatment of metastatic triple-nega-
tive breast cancer (TNBC).[3] However, a later stage, phase III study did not meet its primary
endpoints of demonstrating an improvement in progression-free and overall survival.
Although the clinical development of iniparib was ultimately stopped, publication of clinical
studies of iniparib in combination with a variety of chemotherapy agents continues.[4, 5, 6]
Questions regarding iniparib’s mechanism of action, its metabolites, and their accumulation
and biological activity in tumors and normal tissues remain unanswered. Differences in the
metabolism of iniparib between humans and mice have precluded the use of murine models to
investigate this drug, underscoring the need for alternative models to investigate the potential
use of iniparib in cancer treatment protocols. When comparing studies in human patients and
healthy beagle dogs, it was apparent that similarities in iniparib pharmacokinetics (PK)
between these species exist, suggesting that dogs may be an important model for studying the
true mechanisms of action, activity, and appropriate use of this drug. Specifically, doses of 10–
30 mg/kg in research dogs have produced exposures of drug and metabolites comparable to the
tested human clinical dose of 5.6 mg/kg (G. T. Emmons, personal communication). Plasma
elimination (t1/2) of iniparib is rapid (< 10 to 20 minutes) while that of the IABM and IABA
metabolites is slower (1–2 hours), in both species.
Similarities in iniparib tolerability between human patients and healthy beagles have been
noted as well. When used as a single agent in human patients, toxicity has been minimal, and
safety analyses indicate that the addition of iniparib to standard chemotherapy protocols does
not appreciably add to their toxicity profiles. Single and multiple dose toxicokinetic studies of
iniparib alone in normal beagle dogs have illustrated comparable tolerability at translatable
doses above the human patient regimen (5.6 mg/kg IV twice weekly, see S1 Poster). Although
these studies in human patients and healthy beagles have included few subjects, the data sup-
port translatable PK across species and further allow same-species therapeutic index questions
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to be asked. Collectively, this approach lends valuable support to the comparative approach to
cancer drug development.
The comparative oncology approach, specifically referring to the study of pet dogs with spon-
taneous cancer, offers a potential solution to the lingering questions about iniparib, its metabo-
lites, and their accumulation in tumors. In addition to the similarities in drug metabolism, the
large size of pet dogs and their naturally-occurring, biologically heterogeneous malignancies
allow for the collection of repeated blood and tissue samples to study drug PK and biodistribu-
tion. Such critical questions, when answered by the tumor-bearing dog model, add value to the
current approaches during drug development. Therefore, a clinical trial in tumor-bearing dogs
was designed with the following objectives: 1) to determine plasma and tumor exposures of ini-
parib and its metabolites, linked to tolerable iniparib doses, 2) to determine the therapeutic
index (dose-biologic response and dose-toxicity) of iniparib, 3) to determine iniparib exposure
in normal tissues, and 4) to define tumor iniparib and metabolite levels when used as a single
agent and in combination with carboplatin. The long-term goal is to further validate this canine
comparative oncology model in the development of new anti-cancer agents.
Materials and Methods
Comparative Oncology Trials Consortium (COTC): Clinical Trial
Conduct
All dogs were evaluated uniformly and treated within a defined clinical protocol with Institu-
tional Animal Care and Use Committee (IACUC) approval at each COTC enrollment site
(The Ohio State University, Colorado State University, Auburn University, Texas A&M Uni-
versity, University of California-Davis, University of Missouri, and University of Wisconsin-
Madison). The NCI-COP reviewed the eligibility screening and approved trial entry of each
patient. Informed owner consent was required for trial entry. The goals, infrastructure, and
data reporting of the COTC have been described previously.[7,8] Additionally, a Data/Safety
Monitoring Board (DSMB) is convened for each COTC trial, comprised of 5 COTC investiga-
tors (1 chair and 4 committee members) who are not directly participating in the trial. This
committee reviews all adverse events (AEs) and data generated from the trial on both a sched-
uled and ad-hoc basis depending on the severity and nature of the AEs. Decisions regarding
AE management, dose modification/escalation, and modification of the clinical protocol are
made jointly between the DSMB and Comparative Oncology Program personnel. This veteri-
nary clinical trial in dogs with cancer described herein was conducted through this multi-insti-
tutional consortium. The study protocol was reviewed and approved by each participating
institution’s Institutional Animal Care and Use Committee.
Trial eligibility and enrollment
Client-owned pet dogs weighing> 10 kg with histologically confirmed malignant melanoma,
squamous cell carcinoma, or soft tissue sarcoma were eligible for inclusion in this open-label
prospective clinical trial. Other eligibility criteria required that dogs be free of significant co-
morbid illness with a favorable performance status (grade 0 or 1 modified Eastern Cooperative
Oncology Group (ECOG) performance status), have a measureable tumor(s) 3 cm at the
longest diameter amenable to serial biopsy, and signed owner consent. Dogs with naïve, recur-
rent after previous surgery, or metastatic disease were eligible; however dogs receiving prior
treatment with chemotherapy, immunotherapy, or radiation therapy were excluded. A 7-day
washout period for non-steroidal anti-inflammatory drugs and corticosteroids was required
prior to trial initiation.
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Dogs underwent enrollment evaluation including measurement of tumor burden using cali-
pers, digital photography of tumor burden, complete blood count (CBC), serum biochemical
profile, urinalysis (UA), thoracic radiographs, and abdominal ultrasound examination (if clini-
cally indicated) within 10 days of the first iniparib treatment (Day 1). Dogs were ineligible for
the trial enrollment if the serum creatinine concentration> upper limits of normal, total
serum bilirubin concentration> 2.0 mg/dL, hematocrit< 25%, platelet count< 50,000/μL, or
any grade 2 or higher hematologic and/or biochemical abnormality as assessed by VCOG-CT-
CAE v1.1. [9]
Study schema
Anticipated trial duration for each enrolled dog was 22 days. A schedule of patient evaluation
and diagnostics performed at each time point is summarized in Table 1. Dogs were considered
off study after completion of Day 22 and were free to receive any additional therapy deemed
appropriate by the attending clinician. If disease progression and/or symptomatic deterioration
were documented during the trial period, dogs were removed from the study, and Day 22 col-
lections were performed early.
All tumor measurements were recorded in centimeters and performed independently by 2
clinicians. Although clinical activity was not a study endpoint, tumor measurements were com-
pared between visits and responses determined via RECIST 1.1 criteria. [10] Hematologic and
biochemical evaluation (CBC, serum biochemistry profile, coagulation parameters (PT/PTT),
and UA) were performed at a central laboratory (Antech GLP, Morrisville, NC, USA) under
GLP conditions. On Day 8, an additional CBC, blood urea nitrogen (BUN), and serum creati-
nine were performed at the respective COTC institution to ensure safe iniparib/carboplatin
administration and to evaluate toxicities associated with administration of iniparib alone.
Blood pressures (indirect or mean arterial pressure) were recorded on Days 1 and 8, prior to
iniparib administration and 2 hours after the end of infusion.
Treatment Administration
Iniparib was diluted in 0.9% sodium chloride to a concentration of 0.02 mg/mL to 0.2 mg/mL.
All dogs received iniparib as a 60-minute IV infusion on Days 1, 4, 8, and 11. Also on Day 8, all
dogs received carboplatin. CBCs were performed prior to carboplatin treatment to ensure neu-
trophil counts were> 1500/μL and platelet counts were> 50,000/μL permitting drug adminis-
tration. Carboplatin, at a target dosage of 300 mg/m2 was administered immediately prior to
iniparib administration via standard slow bolus injection.
A 3+3 dose escalation design was employed to allow a minimum of 3 dogs to enroll per
cohort.[11] Dose escalation was performed with a goal of determining if iniparib could be
safely administered at and beyond predicted exposures that are currently being used in the
human clinic. Cohort escalations are denoted in Table 2. Determination of dose equivalency
between dog dosing cohorts and human clinical dosing was based upon comparisons between
Cmax and AUC data collected in normal dogs and a phase I human trial.
Toxicity due to iniparib exposure was assessable within the trial design. Toxicity was
assessed using the Veterinary Cooperative Oncology Group Common Toxicity Criteria for
Adverse Events v 1.1 (VCOG-CTCAE).[9] Attribution of toxicities was designated as due to
drug, disease, research protocol, or other cause. Further, the certainty of attribution was desig-
nated as Unrelated, Unlikely, Possible, Probable or Definite. Dose limiting toxicities (DLT)
were defined as grade 3 or higher toxicity (excluding hematologic, nausea and vomiting) refrac-
tory to standard supportive care, or grade 4 hematologic, nausea or vomiting lasting longer
than 7 days or that necessitated hospitalization. Individual treatment delays or dose reductions
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were allowed if grade 3 or 4 adverse events occurred during the 11-day course of iniparib dos-
ing. The maximally tolerated dose (MTD) was defined as one dose below the maximum
achieved in dose escalation.
Pharmacokinetics
Serum and plasma were collected from all dogs on Days 1, 4, 8 and 11 as outlined in Table 1.
PK analysis of plasma iniparib and selected metabolites (IABA, IABM, GS-conjugate, NAC-
conjugate, Cys-conjugate, and INBA) was performed on samples obtained during and after
drug administration. A 12-point PK collection over 13 hours (0, 30, 55, minutes after start of
infusion, 5, 15, 30 minutes, 1, 2, 4, 6, 8, 12 hours post end of infusion) was performed on Days
1 and 8 of iniparib administration. Plasma PK samples were also collected on Days 4 and 11
before treatment and at the end of infusion, and on Day 15. Serum was collected pre-treatment
on Day 1, and after treatment on Days 1, 4, 8, 11, 15 and 22.
Tumor and normal tissue biopsies also were collected from all dogs to assess iniparib and
selected metabolites (IABA, IABM, GS-conjugate, NAC-conjugate, Cys-conjugate, and INBA)
tissue levels pre- and post therapy. Serial incisional biopsies of the tumor were collected pre-
treatment (Day 1 prior to iniparib administration) and on Days 1 and 8, five minutes post
administration. These biopsies were also collected on Day 15. Individual anesthesia plans were
implemented by clinicians based on each dog’s history and current disease status. Normal tis-
sue sampling from a location adjacent to the tumor (skin, mucosa or muscle) occurred con-
comitantly. At each biopsy time point, two samples were obtained from both the tumor and
adjacent normal tissue. For tumor biopsies, one sample was flash frozen in liquid nitrogen and
Table 1. Schedule of patient evaluations and study procedures.
Action Pre-Treatment Day 1 Day 4 Day 8 Day 11 Day 15 Day 22
Patient Eligibility X
Measurement of tumor burden (caliper measurements) X X X X
Physical Exam X X X X X X X
Chest radiographs X
Digital photo of tumor X X X X
CBC/chemistry/UA/coagulation profile X X X X
Serum and plasma collection X X X X X X X
Iniparib administration (IV over 60 minutes) X X X X
Carboplatin administration X
Tumor Biopsy X X X X
Normal tissue Biopsy X X X X
Owner Assessment Form X X X X X X
Blood pressure measurement X X
doi:10.1371/journal.pone.0149194.t001
Table 2. Iniparib Dose Escalation cohorts in tumor bearing dogs.
Dose Cohort Iniparib dose # of dogs in cohort
1 10 mg/kg (1/2 equivalent human dose) 3
2 20 mg/kg (approximate equivalent human dose) 3
3 35 mg/kg (2x equivalent human dose) 7
4 50 mg/kg (3x equivalent human dose) 3
5 70 mg/kg (4.5x equivalent human dose) 3
doi:10.1371/journal.pone.0149194.t002
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the other placed in formalin, whereas both normal tissue samples were flash frozen in liquid
nitrogen. All biologic samples were frozen and stored at -80°C and batch shipped on Day 22
after collection for analysis using exploratory high resolution liquid chromatography coupled
to mass spectrometry methods. The lower limit of quantification (LLOQ) was 2.00–5.00 ng/mL
in plasma and 2.00–10.00 ng/g in tumors and normal tissues. Plasma and tissue concentrations
for iniparib and metabolites on Day 1 and Day 8 were manually entered in WinNonLin 5.2
software, (Pharsight Corp., USA) using nominal sampling times, for PK analysis. Descriptive
statistics (mean, standard deviation (SD), Coefficient of Variability (CV%)) were calculated on
plasma and tissue concentrations per analyte and treatment group on Day 1 and Day 8.
Results
Nineteen dogs were enrolled between March 2012 and November 2012. Dog age (median: 9
years; range: 3–14), sex (9 castrated males, 1 intact male, 7 spayed females, and 2 intact
females), breed (7 mixed breeds and 12 pure breeds), and body weight (median: 27.5 kg; range:
13.8–90.2) were recorded (Table 3). One of 19 dogs was withdrawn by its owner on Day 3 after
receiving only one dose of iniparib, reducing the number of evaluable dogs in Cohort 3 (35 mg/
kg) from 7 to 6.
The number of dogs per dosing cohort is summarized in Table 2. One dog in the 35 mg/kg
cohort experienced DLT including grade 3 fever, grade 4 neutropenia, and grade 4 thrombocy-
topenia necessitating hospitalization. These events occurred at Day 20 of the treatment cycle.
This cohort was expanded and no additional DLT were observed. One dog in the 70 mg/kg
cohort experienced DLT including grade 3 anorexia and grade 3 diarrhea at Day 12 of the treat-
ment cycle, for which attribution to iniparib was deemed “Probable”. This dog also had DLT
including grade 4 neutropenia and thrombocytopenia at Day 17 of the treatment cycle. This
dog was hospitalized for supportive care for all of these DLT.
Iniparib was not considered the “Probable” cause of all hematologic DLT. However, all fell
within the range for carboplatin neutrophil and platelet nadirs, and therefore the DLT were
attributed to carboplatin alone. All other noted toxicities were mild.
Eighteen dogs were evaluable at Day 22 for tumor response assessment. There were no
objective responses, complete or partial, among any of the dogs at any timepoint of study. Five
of 18 (28%) had progressive disease (PD) while the remaining 13 of 18 (72%) had stable disease
(SD). (Table 3)
PK Results
Moderate to high variability was observed for iniparib and its metabolites plasma exposure lev-
els between animals. Mean PK parameters for each dosing cohort following the 1-hour infusion
of iniparib administered alone (Day 1) and with carboplatin (Day 8) are presented in Table 4.
Following a 1-hour infusion on Day 1, all animals were exposed to iniparib and its metabolites.
Detectable concentrations were above LLOQ up to 2.0 hours, up to 3.0 hours and up to 13.0
hours after the start of the 1-hour infusion for iniparib, for IABM, and for all other metabolites,
respectively regardless of dosage administered. The main quantifiable metabolites in plasma
with highest exposures, regardless of the dose and the day administered were GS-conjugate,
Cys-conjugate, and INBA. Across all dosing cohorts (10–70 mg/kg), iniparib and its metabo-
lites exposures (Cmax and AUC) were roughly similar regardless of whether iniparib was
administered alone (Day 1) or in combination with carboplatin (Day 8).
As observed in plasma, the main quantifiable metabolites in normal and tumor tissues were
GS-conjugate, Cys-conjugate, and INBA; these were quantifiable at all iniparib doses. Normal
and tumor tissue exposure of iniparib and IABA was quantifiable at lower levels, but not at all
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doses or in all dogs, thus precluding the calculation of tumor:normal tissue ratios. IABM was
also quantifiable in tumors at lower levels but was distributed with the highest tumor/plasma
ratios assessed at 1.4 and 1.7 on Day 1 and Day 8, respectively at the dose of 35 mg/kg of ini-
parib. Tumor to plasma ratios for iniparib and metabolites for each dosing cohort following
the 1-hour infusion of iniparib administered alone (Day 1) and with carboplatin (Day 8) are
also presented in Table 4.
Discussion
The value of the comparative oncology model, using pet dogs with spontaneous cancers to
study novel cancer therapies, has been previously described and illustrates the complementary
advantages to the approach.[12,13] Key features of this model system are that it allows investi-
gations to occur in immune-competent, large animals (pet dogs) with naturally occurring
tumors, which confers advantages such as the presence of naturally syngeneic tumor-associated
vasculature and stroma, tumor heterogeneity, and host immune responses. One particular
challenge of the traditional rodent model that the pet dog model overcomes is the ability to col-
lect repeated blood and tissue samples to study drug PK. The large size of dogs makes such
sample collection feasible. Additionally, as is the case with iniparib, the PK and metabolism of
drugs is often more comparable between humans and dogs in contrast to other conventional
preclinical models. Finally, many common canine cancers are comparable to common human
cancers in etiology, biologic behavior, response to therapy, and overall outcome.[14]
Results of this study demonstrate that iniparib can be administered safely in combination
with carboplatin to dogs with naturally occurring cancers at and above dosages relevant to
those used in the human clinic. When carboplatin is added to the treatment regime, toxicity
does not increase beyond that expected with carboplatin alone. Iniparib is cleared rapidly from
Table 3. Patient characteristics.
Patient Gender Age Breed Weight Disease Term Cohort Response
1 Castrated male 12 Labrador Retriever 35.7 kg Soft Tissue Sarcoma 10 mg/kg IV SD
2 Intact female 6 Mixed Breed 31.6 kg Soft Tissue Sarcoma 10 mg/kg IV SD
3 Castrated male 9 Golden Retriever 45.0 kg Fibrosarcoma 10 mg/kg IV SD
4 Castrated male 6 Mixed Breed 22.3 kg Soft Tissue Sarcoma 20 mg/kg IV PD
5 Castrated male 9 Mixed Breed 23.9 kg Soft Tissue Sarcoma 20 mg/kg IV PD
6 Castrated male 11 Golden Retriever 24.6 kg Soft Tissue Sarcoma 20 mg/kg IV PD
7 Castrated male 10 German Shepherd Dog 42.1 kg Soft Tissue Sarcoma 35 mg/kg IV SD
8 Spayed Female 9 Mixed Breed 20.7 kg Soft Tissue Sarcoma 35 mg/kg IV SD
9 Castrated male 14 Mixed Breed 29.2 kg Squamous Cell Carcinoma 35 mg/kg IV SD
10 Spayed Female 11 Rottweiler 40.0 kg Soft Tissue Sarcoma 35 mg/kg IV PD
11 Castrated male 3 Great Dane 90.2 kg Soft Tissue Sarcoma 35 mg/kg IV SD
12 Spayed Female 8 Labrador Retriever 35.2 kg Soft Tissue Sarcoma 35 mg/kg IV SD
13 Intact Male 8 Vizsla 20.6 kg Melanoma 35 mg/kg IV SD
14 Spayed Female 12 Mixed Breed 14.9 kg Soft Tissue Sarcoma 50 mg/kg IV PD
15 Spayed Female 5 Labrador Retriever 27.5 kg Squamous Cell Carcinoma 50 mg/kg IV SD
16 Castrated male 11 Pointer 20.5 kg Soft Tissue Sarcoma 50 mg/kg IV SD
17 Spayed Female 11 Beagle 13.8 kg Spindle Cell Carcinoma 70 mg/kg IV SD
18 Female 7 Mastiff 37.2 kg Mammary Carcinoma 70 mg/kg IV PD
19 Spayed Female 13 Mixed Breed 17.2 kg Soft Tissue Sarcoma 70 mg/kg IV SD
SD: Stable Disease, PD: Progressive Disease
doi:10.1371/journal.pone.0149194.t003
Iniparib in Tumor-Bearing Dogs
PLOS ONE | DOI:10.1371/journal.pone.0149194 February 11, 2016 7 / 11
Table 4. Pharmacokinetics and tissue biodistribution of iniparib and selected metabolites in the tumor-bearing dog.
Compound Dose (mg/kg) Day Plasma Cmax (ng/ml) Plasma AUC (ng*hr/mL) Plasma T1/2z (hr) Ratio Tumor/Plasma
Iniparib 10 1 1340 ± 659 1100** 0.092** NA
20 1 3540 ± 2870 2800 ± 2200 0.13 ± 0.037 0.074
35 1 12400 ± 11100 8000 ± 8200 0.11 ± 0.021 0.073
50 1 11000 ± 9820 9100** 0.13** NA
70 1 24900 ± 19300 9000** 0.11** 0.088
Iniparib 10 8 1620 ± 712 1100 ± 260 0.1 ± 0.013 NA
20 8 3100 ± 1340 2000 ± 800 0.16 ± 0.076 NA
35 8 9080 ± 6150 4300 ± 1300 0.12 ± 0.018 0.057
50 8 11600 ± 11500 NA NA NA
70 8 10500 ± 6870 6400 ± 3700 0.17 ± 0.051 NA
IABM 10 1 7.02 ± 1.84 NA NA NA
20 1 10 ± 1.35 NA NA NA
35 1 29.6 ± 18.2 67 ± 37 0.78 ± 0.14 1.4
50 1 66.6 ± 32.2 97 ± 31 0.91 ± 0.29 NA
70 1 36.3 ± 11.9 NA NA NA
IABM 10 8 6.96** NA NA NA
20 8 12.8 ± 1.45 NA NA NA
35 8 30 ± 14.1 75** 1** 1.7
50 8 37.7 ± 16.8 66** 0.66** NA
70 8 86.6 ± 73.1 NA* NA* NA
IABA 10 1 10.9 ± 5.48 94** 2.5** NA
20 1 16.8 ± 6.61 81±29 2 0.23 NA
35 1 71.7 ± 30 390 ± 180 2.3 0.7 NA
50 1 96.5 ± 27.1 510 ± 170 2.1 0.15 NA
70 1 116 ± 42.4 750 ± 230 2.5 0.57 0.49
IABA 10 8 7.29 ± 4.1 63** 2.7** NA
20 8 13.9 ± 3.11 NA NA NA
35 8 57 ± 22.3 330 ± 210 2.2 ± 0.82 1
50 8 56.4 ± 20.7 270 ± 95 1.9 ± 1.2 NA
70 8 149 ± 56 920 ± 200 2.5 ± 0.9 NA
Glutathione-conjugate 10 1 7020 ± 1370 9200 ± 2100 5.6 ± 3.7 0.52
20 1 13100 ± 4710 18000 ± 5800 6.7 ± 5.2 0.18
35 1 27000 ± 5680 36000 ± 8200 4 ± 2.2 0.28
50 1 55800 ± 9150 73000 ± 14000 2 ± 0.59 0.23
70 1 42500 ± 29800 69000** 2.6** NA
Glutathione-conjugate 10 8 7060 ± 544 9400 ± 1400 2.2 ± 0.12 0.4
20 8 12100 ± 4100 16000 ± 4600 3.2 ± 0.99 0.071
35 8 28100 ± 7050 39000 ± 9100 2.5 ± 0.46 0.56
50 8 41800 ± 3860 64000 ± 7400 2.8 ± 1.9 0.37
70 8 39400 ± 33400 64000 ± 48000 3.1 ± 0.4 NA
N-acetyl-cysteine-conjugate 10 1 14.7** NA NA NA
20 1 31.3 ± 3.7 NA NA NA
35 1 48.3 ± 28.1 290** 3.2** NA
50 1 77.8 ± 21.4 430** 2.2** NA
70 1 92.8 ± 14.2 670** 4.1** NA
N-acetyl-cysteine-conjugate 10 8 11.8 ± 6.71 NA NA NA
20 8 34.2 ± 4.15 NA NA NA
(Continued)
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plasma of tumor-bearing dogs over the dose range of 10–70 mg/kg. However, at dosages up to
70 mg/kg neither iniparib nor its metabolites accumulate significantly in tumor or normal tis-
sues. PK and tolerability data collected in human patients receiving iniparib alone and in com-
bination with gemcitabine/carboplatin chemotherapy revealed striking similarities to data
reported herein.[3,4] Although a high degree of variability was seen, these human data col-
lected from patients receiving 5.6 mg/kg of iniparib twice weekly are comparable to the tumor-
bearing dog dosing cohorts of 10–20 mg/kg of iniparib alone and in combination with carbo-
platin. These results are consistent with previous studies that demonstrate the tolerability but
lackluster performance of iniparib in human clinical trials.[4] Recent studies suggest that clini-
cal benefit could be seen with inparib in combination with temozolomide, and when given at
doses significantly higher than previously studied. The dog model provides an excellent oppor-
tunity to delve further into these observations by virtue of the facile nature of serial biologic
sample collections within individual canine patients and existing clinical expertise among vet-
erinary oncologists with such treatment strategies. The data presented herein provides a natu-
ral platform on which to base such future studies of the relationship between PK, PD and drug
combinations. Furthermore, these data provide significant support to the use of the canine
model, particularly when comparative PK is critical to determining if drug target modulation
Table 4. (Continued)
Compound Dose (mg/kg) Day Plasma Cmax (ng/ml) Plasma AUC (ng*hr/mL) Plasma T1/2z (hr) Ratio Tumor/Plasma
35 8 45.9 ± 13.3 220** 2** NA
50 8 98.1 ± 21.7 480 ± 290 2.6 ± 0.91 NA
70 8 93.8 ± 63.4 NA NA NA
Cysteine-conjugate 10 1 5740 ± 883 15000 ± 3500 3.3 ± 1.8 1.2
20 1 7880 ± 1050 22000** 3.1** 0.6
35 1 16800 ± 4280 42000 ± 17000 3.5 ± 1.2 0.84
50 1 24600 ± 1610 63000 ± 21000 2.3 ± 0.89 0.37
70 1 21300 ± 5370 68000** 2.4** 0.9
Cysteine-conjugate 10 8 5910 ± 648 12000 ± 2100 1.9 ± 0.23 0.72
20 8 7540 ± 1010 19000 ± 3000 2.6 ± 1.1 1.4
35 8 15700 ± 4250 40000 ± 12000 2.5 ± 0.47 0.75
50 8 22300 ± 4720 64000 ± 19000 2.9 ± 1.8 0.52
70 8 23100 ± 9680 63000 ± 25000 2.9 ± 0.6 0.54
INBA 10 1 6200 ± 1510 11000 ± 3900 1.2 ± 0.5 0.29
20 1 16200 ± 4950 27000 ± 4200 1.3 ± 0.2 0.16
35 1 32200 ± 7750 62000 ± 18000 1.3 ± 0.095 0.12
50 1 36400 ± 18000 68000 ± 24000 1.3 ± 0.15 0.16
70 1 55600 ± 15900 150000 ± 31000 1.2 ± 0.058 0.25
INBA 10 8 6280 ± 795 9800 ± 2300 0.82 ± 0.18 0.31
20 8 10500 ± 2250 19000 ± 3800 1.5 ± 0.36 0.3
35 8 29700 ± 6100 57000 ±16000 1.3 ± 0.2 0.16
50 8 30700 ± 16200 54000 ± 22000 1.6 ± 0.44 0.17
70 8 47300 ± 8860 120000 ± 27000 1.2 ± 0.058 0.15
NA = not assessed or not calculable as below the Lower Limit of Quantification (LLOQ) for sample type
Data presented as mean +/- standard deviation
* n = 1;
** n = 2
doi:10.1371/journal.pone.0149194.t004
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occurs at tolerable doses with meaningful accumulation within tumor tissue. Indeed, the lack
of robust understanding of drugs’ PK-PD relationships, target modulation, and predictive bio-
markers are cited as key factors in oncology drug development attrition.[15,16]
Comparative oncology trials often precede or are conducted in parallel with human trials,
and in many cases guide the development of such trials.[17,18] This particular comparative
oncology study with iniparib was performed in parallel with iniparib trials in humans.
Although development of iniparib as an anticancer agent has been terminated, this study dem-
onstrates the potential for the comparative approach to add new data to the totality of drug
development (human and conventional preclinical models) to assist in clarifying PK, PD and
combination tolerability of investigative drugs, all of which are needed for successful drug
development.
In conclusion, this comparative oncology study in tumor-bearing pet dogs confirms that the
PK properties and clinical tolerability of iniparib mirror what is observed in human cancer
patients, both as a single agent and in combination with other chemotherapies. The tissue bio-
distribution data confirms iniparib’s inability to reach relevant tissue levels. This, combined
with knowledge that PARP inhibition is not iniparib’s main mechanism of action may account
for the lackluster results in confirmatory human TNBC clinical trials.
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